Suchergebnisse - "Rui, Hongliang"

PubPharm (26)

1

Activation of the IL-6/STAT3 pathway contributes to the pathogenesis of membranous nephropathy and is a target for Mahuang Fuzi and Shenzhuo Decoction (MFSD) to repair podocyte damage

enthalten in: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 2024

von Zhao, Q. | Dai, H. | Jiang, H. | +10

2

Efficacy and safety of Mahuang Fuzi and Shenzhuo Decoction for treatment of primary membranous nephropathy : a multicenter prospective trial

enthalten in: Renal failure | 2024

von Zhang, N. | Jiang, H. | Dai, H. | +12

3

Celastrol ameliorates lupus by promoting apoptosis of autoimmune T cells and preventing autoimmune response in MRL/lpr mice

enthalten in: Lupus science & medicine | 2024

von Xie, T. | Rui, H. | Liu, H. | +3

4

Experimental models for elderly patients with membranous nephropathy : Application and advancements

enthalten in: Experimental gerontology | 2024

von Tang, X. | Dai, H. | Hu, Y. | +7

5

Corrigendum : MicroRNAs: Potential mediators between particulate matter 2.5 and Th17/Treg immune disorder in primary membranous nephropathy

enthalten in: Frontiers in pharmacology | 2023

von Zhou, X. | Dai, H. | Jiang, H. | +10

ErratumFor: Front Pharmacol. 2022 Sep 21;13:968256. - PMID 36210816

6

Cytokines network in primary membranous nephropathy

enthalten in: International immunopharmacology | 2022

von Zhao, Q. | Dai, H. | Hu, Y. | +8

7

Course monitoring of membranous nephropathy : Both autoantibodies and podocytes require multidimensional attention

enthalten in: Autoimmunity reviews | 2022

von Liu, W. | Huang, G. | Rui, H. | +6

8

Level of interleukin-35 in patients with idiopathic membranous nephropathy and its predictive value for remission time

enthalten in: Frontiers in immunology | 2022

von Zhang, N. | Dai, H. | Dong, X. | +10

9

MicroRNAs : Potential mediators between particulate matter 2.5 and Th17/Treg immune disorder in primary membranous nephropathy

enthalten in: Frontiers in pharmacology | 2022

von Zhou, X. | Dai, H. | Jiang, H. | +10

ErratumIn: Front Pharmacol. 2023 Feb 27;14:1166591. - PMID 36923355

10

Coronary artery bypass grafting vs. percutaneous coronary intervention in coronary artery disease patients with advanced chronic kidney disease : A Chinese single-center study

enthalten in: Frontiers in surgery | 2022

von Li, Y. | Hou, X. | Xu, X. | +6